Homology Medicines Inc (NASDAQ:FIXX) CFO W Bradford Smith sold 6,000 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $16.00, for a total value of $96,000.00. Following the sale, the chief financial officer now owns 6,000 shares in the company, valued at approximately $96,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
W Bradford Smith also recently made the following trade(s):
- On Monday, December 2nd, W Bradford Smith sold 6,000 shares of Homology Medicines stock. The shares were sold at an average price of $16.21, for a total value of $97,260.00.
- On Tuesday, October 1st, W Bradford Smith sold 6,000 shares of Homology Medicines stock. The shares were sold at an average price of $17.39, for a total value of $104,340.00.
Shares of NASDAQ:FIXX opened at $18.32 on Wednesday. The firm has a fifty day moving average price of $13.72 and a two-hundred day moving average price of $17.58. The company has a market cap of $704.55 million, a price-to-earnings ratio of -9.16 and a beta of 0.14. Homology Medicines Inc has a one year low of $11.05 and a one year high of $31.80.
FIXX has been the topic of a number of recent research reports. Oppenheimer started coverage on Homology Medicines in a report on Friday, November 1st. They set a “market perform” rating on the stock. FIX began coverage on Homology Medicines in a report on Thursday, October 31st. They set a “market perform” rating for the company. Zacks Investment Research cut Homology Medicines from a “hold” rating to a “sell” rating in a research report on Friday, November 15th. HC Wainwright set a $36.00 price target on shares of Homology Medicines and gave the stock a “buy” rating in a report on Tuesday, September 24th. Finally, ValuEngine downgraded shares of Homology Medicines from a “buy” rating to a “hold” rating in a report on Monday, November 25th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $31.40.
Homology Medicines Company Profile
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Featured Story: Limitations of the P/E Growth ratio
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.